Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

long-acting amylin analog for the treatment of obesity, the US Federal Trade Commission today granted early termination of the waiting period under the HSR Act. Closing of the license agreement ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. Headline results from a ...